Literature DB >> 30470617

MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges.

Rui Henrique1, Sandra P Nunes2, Carmen Jerónimo3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30470617     DOI： 10.1016/j.eururo.2018.11.014

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  3 in total

Review 1.  Targeting the Immune system and Epigenetic Landscape of Urological Tumors.

Authors:  João Lobo; Carmen Jerónimo; Rui Henrique
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

2.  Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin+ cell abundance.

Authors:  Quan Zhou; Zewei Wang; Han Zeng; Hongyu Zhang; Zhaopei Liu; Qiuren Huang; Jiajun Wang; Yuan Chang; Qi Bai; Li Liu; Yu Zhu; Le Xu; Bo Dai; Jianming Guo; Yu Xia; Yiwei Wang; Jiejie Xu
Journal:  Oncoimmunology       Date:  2020-04-03       Impact factor: 8.110

3.  SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis.

Authors:  Zijia Qin; Hang Tong; Tinghao Li; Honghao Cao; Junlong Zhu; Siwen Yin; Weiyang He
Journal:  Int J Mol Med       Date:  2021-09-22       Impact factor: 4.101
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.